Procopper Intrauterine Levonorgestrel Releasing Device (Azzam’s IUD): A Clinical Dose Finding Study  

Oleh:

Azzam, Mohamed-Ezz-Eldin A ; El-Ghetani, Sherif M. ; Fateen, Baha A.K. ; Rashid, Alaa A.H.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: SGH Medical Journal vol. 1 no. 2 (Jul. 2006), page 131.
Topik: procopper; bleeding index; bleeding score; intrauterine device.

Ketersediaan

Perpustakaan FK Nomor Panggil: S09.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The aim of the project was to compare intrauterine device containing copper and levonorgestrel (Procopper) in a dose finding study, and also compared to ordinary Copper-T 380A. A prospective randomized study was designed to compare Procopper 3.5 and 7 µg/day with Copper-T 380A. The group of women allocated for Procopper 10 µg/day, were of older age with history of menorrhagia and/or failed Copper-T 380A or other Procopper devices. Four groups were selected for the study. Forty women for each of the Procopper devices 3.5, 7 and 10 µg levonorgestrel daily release and the 4th group of also 40 women, was allocated for Copper-T 380A. After informed written consent and patient evaluation, Procopper and Copper devices were applied in the conventional way using withdrawal technique. Women were followed up after 1, 3, 6 and 12 months for the amount of blood, side effects, and pregnancy rate. As the amount of bleeding and incidence of spotting was high for Procopper 3.5 µg, it was withdrawn from the trial after its use for 10 women. Only Procopper I (7 µg) and Procopper II (10 µg) daily release were continued. The amount of blood loss was much less for Procopper I and II devices than Copper-T as expressed in bleeding index and total bleeding score/month and improved hemoglobin (Hb)%. Break through bleeding was more frequent with Procopper I and systemic side effects were more among Procopper II users. Procopper intra-uterine copper device (IUCD) releasing 7 and 10 µg levonorgestrel have got many advantages over ordinary copper including less bleeding, improved Hb%, less pain, infection and pelvic inflammatory disease. A daily release of 7 µg and more were suitable, while 3.5 µg was inconvenient. A higher daily progestogen release is recommended for older age women and/or those with dysfunctional menorrhagia or failed other IUCD(s).

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali